Rsk and Plk1 both suppress DNA-damage checkpoint signaling by phosphorylating and inhibiting MRE11 activity [35, 39], whilst FGFR2 regulates MRE11 expression through the MEK/ERK/POU1F1 pathway in breast cancer [40]. Here, POU1F1 is linked to breast carcinoma.